HK1066243A1 - Mullerian inhibiting substance levels and ovarian response - Google Patents

Mullerian inhibiting substance levels and ovarian response

Info

Publication number
HK1066243A1
HK1066243A1 HK04109165.6A HK04109165A HK1066243A1 HK 1066243 A1 HK1066243 A1 HK 1066243A1 HK 04109165 A HK04109165 A HK 04109165A HK 1066243 A1 HK1066243 A1 HK 1066243A1
Authority
HK
Hong Kong
Prior art keywords
ovarian
mis
response
fertility
treatment
Prior art date
Application number
HK04109165.6A
Other languages
English (en)
Inventor
David B Seifer
David T Maclaughlin
Original Assignee
Univ New Jersey Med
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23216148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1066243(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ New Jersey Med, Gen Hospital Corp filed Critical Univ New Jersey Med
Publication of HK1066243A1 publication Critical patent/HK1066243A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK04109165.6A 2001-08-20 2004-11-19 Mullerian inhibiting substance levels and ovarian response HK1066243A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31354501P 2001-08-20 2001-08-20
PCT/US2002/026605 WO2003016514A1 (en) 2001-08-20 2002-08-20 Mullerian inhibiting substance levels and ovarian response

Publications (1)

Publication Number Publication Date
HK1066243A1 true HK1066243A1 (en) 2005-03-18

Family

ID=23216148

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04109165.6A HK1066243A1 (en) 2001-08-20 2004-11-19 Mullerian inhibiting substance levels and ovarian response

Country Status (15)

Country Link
US (2) US7241577B2 (pt)
EP (1) EP1419239B1 (pt)
JP (1) JP4508639B2 (pt)
AT (1) ATE476663T1 (pt)
AU (1) AU2002324756B2 (pt)
CA (1) CA2457918C (pt)
DE (1) DE60237211D1 (pt)
DK (1) DK1419239T3 (pt)
EA (1) EA012444B1 (pt)
ES (1) ES2350090T3 (pt)
HK (1) HK1066243A1 (pt)
IL (2) IL160254A0 (pt)
NZ (1) NZ547233A (pt)
PT (1) PT1419239E (pt)
WO (1) WO2003016514A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101847B2 (en) * 2002-10-11 2006-09-05 Milkhaus Laboratory, Inc. Method of treating chronic pelvic pain syndrome by administration of chorionic gonadotropin
WO2006127850A1 (en) * 2005-05-24 2006-11-30 Beckman Coulter, Inc. Immunological assays and antibodies for anti-mullerian hormone
EP2199799A1 (en) 2008-12-19 2010-06-23 Institut National de la Recherche Agronomique Method to select animals with a high capacity of embryo production
EP2646833B1 (en) 2010-11-29 2018-02-21 Mote Marine Laboratory, Inc. Fish sexual characteristic determination using peptide hormones
EP2817621A4 (en) * 2012-02-21 2016-02-24 Univ Northwestern DETECTION OF ANTI-MULLERIAN HORMONE IN WHOLE BLOOD
CN105473154A (zh) 2013-03-12 2016-04-06 通用医疗公司 修饰的缪勒抑制物质(mis)蛋白及其用于疾病治疗的用途
WO2015041718A1 (en) 2013-09-20 2015-03-26 The General Hospital Corporation Uses of modified mullerian inhibiting substance (mis) proteins for the treatment of neurodegenerative diseases
AU2014362307A1 (en) * 2013-12-11 2016-06-30 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
MA41629A (fr) * 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
RU2612839C1 (ru) * 2015-10-15 2017-03-13 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ ОММ" Минздрава России) Способ прогноза развития синдрома гиперстимуляции яичников при применении вспомогательных репродуктивных технологий
US10175252B2 (en) 2016-02-04 2019-01-08 American Infertility Of New York, P.C. Diagnosis, and anti-mullerian hormone (AMH) administration for treatment, of infertility for good-, intermediate- and poor-prognosis patients for in vitro fertilization in view of logistic regression models
US11518793B2 (en) 2016-12-14 2022-12-06 The General Hospital Corporation Mullerian inhibiting substance (MIS) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792601A (en) * 1982-03-01 1988-12-20 The General Hospital Corporation Monoclonal antibody to mullerian inhibiting substance
US5310880A (en) * 1991-04-12 1994-05-10 The General Hospital Corporation Purification of Mullerian inhibiting substance
WO1993019177A1 (en) * 1992-03-18 1993-09-30 The General Hospital Corporation FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY
EP1074265A1 (en) * 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility

Also Published As

Publication number Publication date
CA2457918A1 (en) 2003-02-27
EA200400333A1 (ru) 2004-10-28
EP1419239B1 (en) 2010-08-04
ATE476663T1 (de) 2010-08-15
US7241577B2 (en) 2007-07-10
US20030124620A1 (en) 2003-07-03
JP2005502862A (ja) 2005-01-27
US20070248544A1 (en) 2007-10-25
PT1419239E (pt) 2010-11-08
EP1419239A1 (en) 2004-05-19
US7427486B2 (en) 2008-09-23
IL160254A (en) 2010-04-15
EA012444B1 (ru) 2009-10-30
NZ547233A (en) 2008-11-28
WO2003016514A1 (en) 2003-02-27
ES2350090T3 (es) 2011-01-18
CA2457918C (en) 2013-11-26
AU2002324756B2 (en) 2008-08-07
DE60237211D1 (de) 2010-09-16
IL160254A0 (en) 2004-07-25
EP1419239A4 (en) 2006-01-11
JP4508639B2 (ja) 2010-07-21
DK1419239T3 (da) 2010-11-22

Similar Documents

Publication Publication Date Title
HK1066243A1 (en) Mullerian inhibiting substance levels and ovarian response
MY127234A (en) Methods for assessing, improving, or maintaining urogenital health in postmenopausal women
WO2002082904A3 (en) Method of treating or retarding the development of blindness
MY146986A (en) Methods for treating interleukin-6 related diseases
SG135193A1 (en) Dosing schedule for erbb2 anticancer agents
WO2005052139A3 (en) Method of inducing memory b cell development and terminal differentiation
TR200102977T2 (tr) Yeni tedavi yöntemi.
NZ294446A (en) Stem cell proliferation inhibitors, haemoglobin chains used for the treatment of autoimmune diseases.
WO2006048877A3 (en) Treatment of b-cell malignancies with fgfr3 inhibitors
BR0110759A (pt) Métodos para modular o crescimento de uma célula, e para o tratamento e/ ou profilaxia de uma condição distinguida pelo crescimento celular aberrante, indesejável ou de outro modo não apropriado em um mamìfero, uso de um agente capaz de modular a atividade funcional de esfingosina quinase, composição farmacêutica, e, método de diagnose de uma condição, ou uma predisposição ou resistência a uma condição, distinguida pelo crescimento celular aberrante, indesejável, ou de outro modo não apropriado em um mamìfero
BR9906926A (pt) Composições e métodos para tratamento de células tendo dna de minuto duplo
MD2196B2 (ro) Criptoficine, procedeu de obţinere, compoziţii farmaceutice pe baza acestora, metodă de inhibare a proliferării celulelor mamiferelor şi metodă de atenuare a stării patologice cauzate de hiperproliferarea celulelor mamiferelor
WO2001007028A3 (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
DE69722809D1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)-antagonisten und inhibitoren der hautmastzell-degranulation
IL147294A0 (en) USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGUATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS
EA200300750A1 (ru) Применение антигестагенов для ингибирования ускоренного созревания эндометрия в процессе лечения бесплодия
BG101158A (en) Establishment of tonic overial secretion of estrogen for continuous therapeutical regimen
EP1512755A3 (en) Markers for prostate cancer
MXPA03009448A (es) Inhibidores de aromatasa para tratamiento de infertilidad.
PT1121108E (pt) Nova utilizacao terapeutica de compostos com actividade beta-3-agonista
AUPR077900A0 (en) Immunodiagnosis
Das The relationship between pro-inflammatory cytokines and prostaglandin production in the human amnion
UA51537A (uk) Спосіб лікування затримки статевого розвитку у хлопців-підлітків з попереднім визначенням його ефективності
UA27332U (en) Method for predicting disorders of menstrual cycle in women of fertile age
UA30550A (uk) Спосіб лікування неплідності у жінок з гіперпролактинемією

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220819